KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

Learn how eczema presents differently on skin of color and the impact on mental health. Find resources for identification, ...

Rocatinlimab, administered subcutaneously, results in clinically meaningful improvements in patients with moderate-to-severe ...

Anzupgo (R) (delgocitinib cream) is currently approved in Canada, United States, European Union, United Kingdom, Switzerland and the United Arab Emirates under the brand name Anzupgo (R) for the ...

An international team of investigators has reported results from the first Phase III clinical trials of rocatinlimab, a novel ...

LEO Pharma Inc., a global leader in dermatology, is pleased to announce the availability of Anzupgo® (delgocitinib cream) ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

When searching for answers, expert advice matters. Here’s what dermatologists recommend to help caregivers confidently manage moderate to severe eczema in kids.

The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

Jeremy Rabe visits with TV super star, Tori Spelling, and Dr. Adam Friedman about treatment options for severe eczema. From red carpet events to carpool selfies and everything in between, actress, ...